Terence M. Williams, MD, PhD, discussed the phase 1 DINOMITE trial of radiation therapy and papaverine in rectal cancer at ...

In response to the proposal presented by the Dr Reddy's Laboratories, the Subject Expert Committee (SEC) functional under the ...

Massive Bio, a global company specializing in AI-powered clinical trial matching and oncology data solutions, is participating in the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, ...

Zilovertamab vedotin, an antibody drug conjugate (ADC) developed by Merck & Co (MSD) to treat diffuse large B-cell lymphoma ...

PepGen (PEPG) announced that based on the levels of dystrophin protein measured in the 10 mg/kg cohort of its CONNECT1-EDO51 study investigating PGN-EDO51 in Duchenne muscular dystrophy patients ...

Intellia’s stock fell 23% after one patient in its Phase III MAGNITUDE trial developed severe liver toxicity that later ...

The FDA biologics license application for patritumab deruxtecan in EGFR+ NSCLC has been withdrawn following discussions with ...

Vakharia insights from the ARCHER trial on geographic atrophy treatment for dry AMD, highlighting promising results and ...

Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, today announced the presentation of two new abstracts at the 2025 American Society of ...

Among patients with chronic hypoparathyroidism, palopegteriparatide improved skeletal dynamics and renal function at 2 years, according to new data from the PaTHway trial. As Healio previously ...

US agency’s new policy could abruptly end studies of infectious diseases and cancer, leaving researchers scrambling for funds ...

Immuron has three therapeutic products under development: IMM-124E (Travelan ®) for traveller's diarrhea; IMM-529 for Clostridioides difficile infection and IMM-986 for Vancomycin-resistant ...